NASDAQ:CALC CalciMedica (CALC) Stock Forecast, Price & News $2.64 -0.11 (-4.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$2.59▼$2.9950-Day Range$2.64▼$3.8752-Week Range$1.00▼$8.59Volume8,990 shsAverage Volume6,856 shsMarket Capitalization$14.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media About CalciMedica (NASDAQ:CALC) StockCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.Read More CALC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALC Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comCalciMedica (NASDAQ:CALC) Shares Down 4% September 6, 2023 | finance.yahoo.comCalciMedica Announces Upcoming Presentations and Events in SeptemberSeptember 24, 2023 | The Oxford Club (Ad)2,164% from AI stock in a... month?That's the potential of Multi-millionaire trader Nate Bear's new strategy he calls "One Ticker Payouts". It involves one ticker...one trade...every week. How is this possible? Click here to see all the details and proof for yourself (the next One Ticker Payout is this upcoming MONDAY)>> August 31, 2023 | finance.yahoo.comCalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023August 11, 2023 | finance.yahoo.comCalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate UpdatesAugust 9, 2023 | finance.yahoo.comCalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)July 21, 2023 | wsj.comCalciMedica Inc.July 13, 2023 | finance.yahoo.comCALC - CalciMedica, Inc.September 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 20, 2023 | benzinga.comEF Hutton Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $17June 12, 2023 | msn.comCalciMedica will be relisted on NasdaqJune 12, 2023 | finance.yahoo.comCalciMedica Announces Relisting on NasdaqJune 6, 2023 | finance.yahoo.comCalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)May 23, 2023 | finance.yahoo.comLife Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and DevelopmentMay 16, 2023 | morningstar.comCalciMedica Inc Ordinary SharesMay 15, 2023 | finance.yahoo.comCalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate UpdatesMay 9, 2023 | marketwatch.comLargest Companies in the Acute Pancreatitis Market Drives Growth High 2023-2030May 2, 2023 | marketwatch.comIon Channel Modulators Market 2023 with Leading Players and Growth by 2030April 26, 2023 | marketwatch.comIndustry Experts Predict Acute Pancreatitis Market Growth 2023-2030See More Headlines Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address CALC Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALC CUSIPN/A CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-188.37% Return on Assets-155.88% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$23.35 per share Price / Book0.11Miscellaneous Outstanding Shares5,660,000Free Float2,644,000Market Cap$14.94 million OptionableNot Optionable Beta1.08 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. A. Rachel Leheny Ph.D. (Age 60)CEO & Director Mr. Eric W. Roberts (Age 59)Chief Bus. Officer & Vice Chairman Mr. Michael J. Dunn MBA (Age 67)Pres & COO Dr. Anjana Rao Ph.D.Co-Founder and Scientific AdvisorDr. Patrick Hogan Ph.D.Co-Founder and Scientific AdvisorDr. Stefan Feske M.D.Co-Founder and Scientific AdvisorDr. Kenneth A. Stauderman Ph.D. (Age 70)Co-Founder & Chief Scientific Officer Mr. Daniel E. Geffken M.B.A. (Age 66)MBA, Interim Chief Financial Officer Cindy ReiedenbergAccountantMr. John M. Dunn J.D. (Age 71)Gen. Counsel More ExecutivesKey CompetitorsProMIS NeurosciencesNASDAQ:PMNVascular BiogenicsNASDAQ:VBLTOrgenesisNASDAQ:ORGSLipocineNASDAQ:LPCNEdesa BiotechNASDAQ:EDSAView All CompetitorsInsiders & InstitutionsEric W RobertsBought 736 shares on 8/25/2023Total: $2,340.48 ($3.18/share)Eric W RobertsBought 1,750 shares on 8/21/2023Total: $5,687.50 ($3.25/share)Meritage Portfolio ManagementBought 10,000 shares on 7/31/2023Ownership: 0.177%BML Capital Management LLCBought 88,781 shares on 7/24/2023Ownership: 1.568%Eric W RobertsBought 1,200 shares on 6/26/2023Total: $4,440.00 ($3.70/share)View All Insider TransactionsView All Institutional Transactions CALC Stock - Frequently Asked Questions Should I buy or sell CalciMedica stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CalciMedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CALC shares. View CALC analyst ratings or view top-rated stocks. How have CALC shares performed in 2023? CalciMedica's stock was trading at $5.71 at the beginning of 2023. Since then, CALC shares have decreased by 53.8% and is now trading at $2.64. View the best growth stocks for 2023 here. When is CalciMedica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our CALC earnings forecast. How were CalciMedica's earnings last quarter? CalciMedica, Inc. (NASDAQ:CALC) announced its earnings results on Thursday, August, 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by $0.09. What is CalciMedica's stock symbol? CalciMedica trades on the NASDAQ under the ticker symbol "CALC." Who are CalciMedica's major shareholders? CalciMedica's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (1.57%) and Meritage Portfolio Management (0.18%). View institutional ownership trends. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CalciMedica's stock price today? One share of CALC stock can currently be purchased for approximately $2.64. How much money does CalciMedica make? CalciMedica (NASDAQ:CALC) has a market capitalization of $14.94 million. How can I contact CalciMedica? CalciMedica's mailing address is 203 REDWOOD SHORES PARKWAY SUITE 620, REDWOOD CITY CA, 94065. The official website for the company is www.graybug.vision. The company can be reached via phone at 858-952-5500 or via email at ir@graybug.vision. This page (NASDAQ:CALC) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.